TOPU
CRSP icon

Trustees of Princeton University’s CRISPR Therapeutics CRSP Stock Holding History

Trustees of Princeton University’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,312
Closed -$1.03M – 6
2020
Q3 		$1.03M Buy
+12,312
New +$1.09M 1.38% 5

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Trustees of Princeton University's CRSP Position: Q4 2020 in Review

Trustees of Princeton University sold out of CRISPR Therapeutics (CRSP) in Q4 2020, closing a stake of 12,312 shares — an estimated $1.03M sold.

Trustees of Princeton University first reported a position in CRSP in Q3 2020 and held it in 1 quarter. The position peaked at $1.03M in Q3 2020. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

  • Trustees of Princeton University reported no remaining CRISPR Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Trustees of Princeton University sold 12,312 CRISPR Therapeutics shares in Q4 2020, an estimated $1.03M.
  • Trustees of Princeton University first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 1 quarter.
  • Trustees of Princeton University's CRISPR Therapeutics position peaked at $1.03M in Q3 2020.
  • 412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Trustees of Princeton University's 13F filing for Q4 2020, filed 9 Feb 2021.